VOL. 14, ISSUE 2, 2025
Robert Fox, MD Managing Director
Ruth Ann Marrie, MD, PhD Scientific Director
Amber Salter, PhD Coordinating Center Director
Gary R. Cutter, PhD Scientific Advisor
Alexis Novak, MS Managing Editor
John Fredieu, PhD Medical Writer and Editor
Samantha Lancia, MS Technical Editor
Mudita Sharma, MS Analyst
PUBLISHER
TulipMediaGroup. com
Jessica Saulnier Managing Editor
Tania McIntyre Graphic Designer
Robyn Legacy Project Manager
PHOTOGRAPHY All images sourced from Tulip Media Group or iStock. com unless otherwise identified.
NARCOMS is a project of the Consortium of Multiple Sclerosis Centers( CMSC). For more information on the CMSC, visit www. mscare. org.
NARCOMS Now acknowledges and appreciates the corporate support that provides unrestricted educational grants through the Foundation of the CMSC toward production costs of NARCOMS Now, including printing and mailing. No control or influence in the content of NARCOMS Now or access to NARCOMS data is provided in return for this support. For any questions regarding NARCOMS Now funding please call 1-214-648-4583 or email us at MSRegistry @ narcoms. org.
Dear Readers,
WELCOME TO
NARCOMS Now
This issue of NARCOMS Now focuses on research in progressive multiple sclerosis( MS) and recent clinical trials assessing the safety and efficacy of new treatments. Progressive MS is characterized by a slow accumulation of disability and a worsening of symptoms over time.
In the Feature Focus, we discuss recent clinical trials that explore treatments that may slow the progression of disability in non-relapsing secondary progressive MS, which has been difficult to treat. In addition, we discuss the difficulties in progressive MS research and approaches that have shown promise in advancing new treatments with Jeremy Chataway, MA, PhD, FRCP, Professor of Neurology, University College London.
In Snapshot, we demonstrate how NARCOMS participant data can reveal characteristics of the disease course of progressive MS that are similar or different between men and women.
In the MS News section, we discuss a study that investigates how a ketogenic diet influences the immune system in people with MS. In addition, we summarize a study that investigates whether people with MS who participated in a ketogenic diet study experienced lasting health and dietary benefits, even outside a controlled clinical trial. Both studies support further research into how diet affects MS symptoms or disease characteristics. Finally, we discuss a study with promising results for people with non-relapsing secondary progressive multiple sclerosis.
As always, we appreciate your participation in the NARCOMS registry and thank you for your continued effort and contribution to MS research!
Sincerely,
Robert Fox, MD
Managing Director, NARCOMS
3